Abstract
The majority of patients diagnosed with chronic lymphocytic leukaemia (CLL) will ultimately die of their disease. Stem cell transplantation (SCT) remains the only treatment modality capable of cure, but has traditionally been associated with very high morbidity and mortality. We review the results of myeloablative autologous and allogeneic SCT in CLL, discuss the evolution of the new non-myeloablative approaches, and make recommendations for when SCT should be considered in patients with CLL.
| Original language | English |
|---|---|
| Pages (from-to) | 53-60 |
| Number of pages | 8 |
| Journal | Hematological Oncology |
| Volume | 27 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 2009 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Alemtuzumab
- Bone marrow transplantation
- Reduced intensity conditioning
- Rituximab
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver